HeartSciences Property, Plant, and Equipment 2022-2025 | HSCS
HeartSciences property, plant, and equipment from 2022 to 2025. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
| HeartSciences Annual Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2025 | $0 |
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $0 |
| HeartSciences Quarterly Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2025-04-30 | $0 |
| 2025-01-31 | $0 |
| 2024-10-31 | $0 |
| 2024-07-31 | $0 |
| 2024-04-30 | $0 |
| 2024-01-31 | $0 |
| 2023-10-31 | $0 |
| 2023-07-31 | $0 |
| 2023-04-30 | $0 |
| 2023-01-31 | $0 |
| 2022-10-31 | $0 |
| 2022-07-31 | $0 |
| 2022-04-30 | $0 |
| 2022-01-31 | |
| 2021-10-31 | |
| 2021-07-31 | |
| 2021-04-30 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.004B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $47.457B | 60.38 |
| Hims & Hers Health (HIMS) | United States | $12.904B | 134.07 |
| Doximity (DOCS) | United States | $11.414B | 52.84 |
| Tempus AI (TEM) | United States | $11.164B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.284B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.801B | 59.38 |
| Hinge Health (HNGE) | United States | $3.571B | 0.00 |
| Privia Health (PRVA) | United States | $2.402B | 164.21 |
| 10x Genomics (TXG) | United States | $1.737B | 0.00 |
| Schrodinger (SDGR) | United States | $1.631B | 0.00 |
| Phreesia (PHR) | United States | $1.585B | 0.00 |
| Azenta (AZTA) | United States | $1.576B | 73.25 |
| Enovis (ENOV) | United States | $1.573B | 8.77 |
| Clover Health Investments (CLOV) | United States | $1.545B | 0.00 |
| Omnicell (OMCL) | United States | $1.324B | 23.36 |
| Evolent Health (EVH) | United States | $1.166B | 99.30 |
| Claritev (CTEV) | United States | $0.652B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.559B | 0.00 |
| Standard BioTools (LAB) | United States | $0.532B | 0.00 |
| Veradigm (MDRX) | United States | $0.503B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.487B | 0.00 |
| Talkspace (TALK) | United States | $0.421B | 125.75 |
| TruBridge (TBRG) | United States | $0.353B | 783.33 |
| Outset Medical (OM) | United States | $0.328B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.270B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.258B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.240B | 0.00 |
| CapsoVision (CV) | United States | $0.185B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.161B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.160B | 0.00 |
| American Well (AMWL) | United States | $0.140B | 0.00 |
| Pulmonx (LUNG) | United States | $0.134B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.118B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.118B | 0.00 |
| CareCloud (CCLD) | United States | $0.104B | 3.95 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.099B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.083B | 0.00 |
| 111 (YI) | China | $0.063B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.052B | 0.00 |
| HeartBeam (BEAT) | United States | $0.043B | 0.00 |
| Zhongchao (ZCMD) | China | $0.026B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.022B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.008B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| PROFUSA (PFSA) | United States | $0.004B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.000B | 0.00 |